Vergelijking

Linaclotid vs. Terlipressin

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

851199-59-2

14636-12-5

Molecuulmassa

1526.74 g/mol

1227.37 g/mol

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Linaclotid

Linaclotide activates the guanylate cyclase-C receptor on the luminal surface of the intestinal epithelium. This raises cyclic GMP (cGMP), increases secretion of chloride and bicarbonate into the lumen, raises stool fluid content and accelerates transit; pain signaling is also modulated.

Terlipressin

Terlipressin is slowly converted in the body to lysine-vasopressin by cleavage of the three N-terminal glycyl residues (reservoir effect) and activates V1 receptors. The splanchnic vasoconstriction improves renal perfusion in hepatorenal syndrome.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Linaclotid	Terlipressin
Duitsland	Op recept	Op recept
Verenigde Staten	Op recept	Op recept

Volledige vermeldingen

Linaclotid

Volledige vermelding →

Terlipressin

Volledige vermelding →

Frequently asked questions

What is the difference between Linaclotid and Terlipressin?: Linaclotid is classified as "Onderzoek (overig)", while Terlipressin is classified as "Onderzoek (overig)". Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Terlipressin: Terlipressin is a 12-amino-acid vasopressin analog and prodrug of lysine-vasopressin. As a V1 receptor agonist it is vasoconstrictive and is approved for hepatorenal syndrome (FDA 2022, Terlivaz). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Linaclotid or Terlipressin?: The highest available evidence level is "Humane RCT" for Linaclotid and "Humane RCT" for Terlipressin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Linaclotid and Terlipressin in Germany and the United States?: Duitsland: Linaclotid — Op recept, Terlipressin — Op recept. Verenigde Staten: Linaclotid — Op recept, Terlipressin — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Linaclotid

Terlipressin

Duitsland

Op recept

Verenigde Staten

Op recept

Frequently asked questions

What is the difference between Linaclotid and Terlipressin?

Linaclotid is classified as "Onderzoek (overig)", while Terlipressin is classified as "Onderzoek (overig)". Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Terlipressin: Terlipressin is a 12-amino-acid vasopressin analog and prodrug of lysine-vasopressin. As a V1 receptor agonist it is vasoconstrictive and is approved for hepatorenal syndrome (FDA 2022, Terlivaz). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Linaclotid or Terlipressin?

The highest available evidence level is "Humane RCT" for Linaclotid and "Humane RCT" for Terlipressin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Linaclotid and Terlipressin in Germany and the United States?

Duitsland: Linaclotid — Op recept, Terlipressin — Op recept. Verenigde Staten: Linaclotid — Op recept, Terlipressin — Op recept. These are factual summaries with source and review date on the individual pages.